All patients | |
---|---|
Total Number of included eyes | 101 |
Resolution of subretinal fluid | |
Worsened | 2 (2%) |
Persistent | 31 (31%) |
Recurrent | 2 (2%) |
Partially resolved | 12 (12%) |
Completely resolved | 54 (54%) |
BCVA development | |
Baseline | 0.35 ± 0.3 |
Last follow up | 0.27 ± 0.31 |
P | 0.02* |
Gain | − 0.07 ± 0.2 |
Patients with > 5 letters loss | 13 (13%) |
Patients with stability | 53 (53%) |
Patients with > 5 letter gain | 35 (35%) |
CRT reduction | |
Baseline | 325 ± 130 |
Last follow up | 255 ± 115 |
P | < 0.001* |
Loss | − 70 ± 143 |
Number of MSP treatment | 1.34 (1–3) |
Additional treatment with other treatment modality | 9/101 (9%) |
adverse events from laser | 0/101 (0%) |